<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847297</url>
  </required_header>
  <id_info>
    <org_study_id>40393-10/2020/EÜIG</org_study_id>
    <nct_id>NCT04847297</nct_id>
  </id_info>
  <brief_title>Preoperative Biliary Drainage in Malignant Biliary Obstruction</brief_title>
  <acronym>PEAR</acronym>
  <official_title>Preoperative Biliary Drainage in Malignant Biliary Obstruction - an Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first alarming symptom of a malignancy of the pancreas or periampullary tumor can be&#xD;
      obstructive jaundice (OJ). Pancreato-duodenectomy (PD) combined with oncological treatment&#xD;
      can provide long disease-free survival in resectable cases. The literature regarding the&#xD;
      preoperative biliary drainage is controversial. The aim of this multicenter, prospective&#xD;
      observational cohort study is to investigate the role of preoperative drainage, and to&#xD;
      compare it with surgery alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of serious complications</measure>
    <time_frame>120 days</time_frame>
    <description>rate of serious complications after preoperative biliary drainage and surgery&#xD;
Pancreatitis&#xD;
New onset of cholecystitis&#xD;
Cholangitis&#xD;
Perforation&#xD;
Hemorrhage after endoscopic retrograde cholangiopancreatography (ERCP)&#xD;
Related to stent&#xD;
Occlusion&#xD;
Need for exchange Related to surgery&#xD;
Pancreas anastomosis leakage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of serious complications</measure>
    <time_frame>120 days</time_frame>
    <description>rate of serious complications after preoperative biliary drainage and surgery defined as:&#xD;
Pancreatitis&#xD;
New onset of cholecystitis&#xD;
Cholangitis&#xD;
Perforation&#xD;
Hemorrhage after endoscopic retrograde cholangiopancreatography (ERCP)&#xD;
Related to stent&#xD;
Occlusion&#xD;
Need for exchange Related to surgery&#xD;
Pancreas anastomosis leakage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>120 days</time_frame>
    <description>Length of hospitalization after biliary drainage and surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of mortality among groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>120 days</time_frame>
    <description>Rate of mortality among the groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">353</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Preoperative biliary drainage and pancreatoduodenectomy</arm_group_label>
    <description>Patients receiving preoperative biliary drainage before the removal of the tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatoduodenectomy only</arm_group_label>
    <description>Patients undergoing only surgical intervention, without preoperative drainage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preoperative drainage and pancreatoduodenectomy</intervention_name>
    <description>Preoperative biliary drainage before surgical removal of the tumor</description>
    <arm_group_label>Preoperative biliary drainage and pancreatoduodenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatoduodenectomy</intervention_name>
    <description>Pancreatic tumor resection without previous preoperative biliary drainage</description>
    <arm_group_label>Pancreatoduodenectomy only</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (serum and plasma) from all patients will be stored in the Biobank in order to&#xD;
      study laboratory parameters later if required (eg, the laboratory could not measure it), and&#xD;
      in order to build up a biobank for later clinical studies to which all participants will be&#xD;
      given informed consent. The samples will be stored at -80°C.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be patients diagnosed with malignant biliary obstruction who meet&#xD;
        all the inclusion criteria but no exclusion criteria. All patients admitted with malignant&#xD;
        biliary obstruction with- or without biliary intervention prior to the surgery in the&#xD;
        participating hospitals will be assessed for eligibility&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 years&#xD;
&#xD;
          2. OJ of malignant origin (pancreatic head or periampullary tumor)&#xD;
&#xD;
          3. Total bilirubin level ≥ 40 μmol per liter&#xD;
&#xD;
          4. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Proved metastasis&#xD;
&#xD;
          2. Irresectable tumor&#xD;
&#xD;
          3. Neo-adjuvant chemotherapy&#xD;
&#xD;
          4. Co-existing malignancy&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Patients not fit for resection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Péter Hegyi</last_name>
    <role>Study Chair</role>
    <affiliation>Insitute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ákos Szűcs</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Surgical Department of the University of Semmelweis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ákos Szűcs</last_name>
    <phone>06305359443</phone>
    <email>szucs.akos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Péter Hegyi</last_name>
    <phone>06703751031</phone>
    <email>hegyi2009@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Abdeldayem H, Ghoneim E, Refaei AA, Abou-Gabal A. Obstructive jaundice promotes intestinal-barrier dysfunction and bacterial translocation: experimental study. Hepatol Int. 2007 Dec;1(4):444-8. doi: 10.1007/s12072-007-9018-1. Epub 2007 Sep 20.</citation>
    <PMID>19669340</PMID>
  </reference>
  <reference>
    <citation>Assimakopoulos SF, Scopa CD, Vagianos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. World J Gastroenterol. 2007 Dec 28;13(48):6458-64. Review.</citation>
    <PMID>18161914</PMID>
  </reference>
  <reference>
    <citation>Kuzu MA, Kale IT, Cöl C, Tekeli A, Tanik A, Köksoy C. Obstructive jaundice promotes bacterial translocation in humans. Hepatogastroenterology. 1999 Jul-Aug;46(28):2159-64.</citation>
    <PMID>10521960</PMID>
  </reference>
  <reference>
    <citation>Ito Y, Bethea NW, Baker GL, McCuskey MK, Urbaschek R, McCuskey RS. Hepatic microcirculatory dysfunction during cholestatic liver injury in rats. Microcirculation. 2003 Oct;10(5):421-32.</citation>
    <PMID>14557825</PMID>
  </reference>
  <reference>
    <citation>Abrahám S, Szabó A, Kaszaki J, Varga R, Eder K, Duda E, Lázár G, Tiszlavicz L, Boros M, Lázár G Jr. Kupffer cell blockade improves the endotoxin-induced microcirculatory inflammatory response in obstructive jaundice. Shock. 2008 Jul;30(1):69-74. doi: 10.1097/SHK.0b013e31815dceea.</citation>
    <PMID>18562926</PMID>
  </reference>
  <reference>
    <citation>Kennedy JA, Clements WD, Kirk SJ, McCaigue MD, Campbell GR, Erwin PJ, Halliday MI, Rowlands BJ. Characterization of the Kupffer cell response to exogenous endotoxin in a rodent model of obstructive jaundice. Br J Surg. 1999 May;86(5):628-33.</citation>
    <PMID>10361183</PMID>
  </reference>
  <reference>
    <citation>Minter RM, Fan MH, Sun J, Niederbichler A, Ipaktchi K, Arbabi S, Hemmila MR, Remick DG, Wang SC, Su GL. Altered Kupffer cell function in biliary obstruction. Surgery. 2005 Aug;138(2):236-45.</citation>
    <PMID>16153432</PMID>
  </reference>
  <reference>
    <citation>Sheen-Chen SM, Chau P, Harris HW. Obstructive jaundice alters Kupffer cell function independent of bacterial translocation. J Surg Res. 1998 Dec;80(2):205-9.</citation>
    <PMID>9878315</PMID>
  </reference>
  <reference>
    <citation>Kloek JJ, Heger M, van der Gaag NA, Beuers U, van Gulik TM, Gouma DJ, Levi M. Effect of preoperative biliary drainage on coagulation and fibrinolysis in severe obstructive cholestasis. J Clin Gastroenterol. 2010 Oct;44(9):646-52. doi: 10.1097/MCG.0b013e3181ce5b36.</citation>
    <PMID>20142756</PMID>
  </reference>
  <reference>
    <citation>N Shachiri DK, D Tonev, M Shishenkov. Hemostasiologic Changes during Hepatobiliary Surgery in Patients with Obstructive Jaundice: Pathophysiology and Clinical Considerations. The Internet Journal of Anesthesiology. 2010;28(1).</citation>
  </reference>
  <reference>
    <citation>Betjes MG, Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol. 2006 Mar-Apr;19(2):229-33.</citation>
    <PMID>16736428</PMID>
  </reference>
  <reference>
    <citation>Uslu A, Taşli FA, Nart A, Postaci H, Aykas A, Bati H, Coşkun Y. Human kidney histopathology in acute obstructive jaundice: a prospective study. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1458-65. doi: 10.1097/MEG.0b013e32833f71f6.</citation>
    <PMID>20881503</PMID>
  </reference>
  <reference>
    <citation>Padillo J, Puente J, Gómez M, Dios F, Naranjo A, Vallejo JA, Miño G, Pera C, Sitges-Serra A. Improved cardiac function in patients with obstructive jaundice after internal biliary drainage: hemodynamic and hormonal assessment. Ann Surg. 2001 Nov;234(5):652-6.</citation>
    <PMID>11685028</PMID>
  </reference>
  <reference>
    <citation>Klinkenbijl JH, Jeekel J, Schmitz PI, Rombout PA, Nix GA, Bruining HA, van Blankenstein M. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg. 1993 Dec;80(12):1575-8.</citation>
    <PMID>7507785</PMID>
  </reference>
  <reference>
    <citation>Trede M, Schwall G. The complications of pancreatectomy. Ann Surg. 1988 Jan;207(1):39-47.</citation>
    <PMID>3276272</PMID>
  </reference>
  <reference>
    <citation>Kimmings AN, van Deventer SJ, Obertop H, Rauws EA, Huibregtse K, Gouma DJ. Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut. 2000 May;46(5):725-31.</citation>
    <PMID>10764720</PMID>
  </reference>
  <reference>
    <citation>van der Gaag NA, Kloek JJ, de Castro SM, Busch OR, van Gulik TM, Gouma DJ. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg. 2009 Apr;13(4):814-20. doi: 10.1007/s11605-008-0618-4. Epub 2008 Aug 23. Review.</citation>
    <PMID>18726134</PMID>
  </reference>
  <reference>
    <citation>Hatfield AR, Tobias R, Terblanche J, Girdwood AH, Fataar S, Harries-Jones R, Kernoff L, Marks IN. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet. 1982 Oct 23;2(8304):896-9.</citation>
    <PMID>6126752</PMID>
  </reference>
  <reference>
    <citation>Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS, Longmire WP Jr. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg. 1985 May;201(5):545-53.</citation>
    <PMID>2986562</PMID>
  </reference>
  <reference>
    <citation>Wig JD, Kumar H, Suri S, Gupta NM. Usefulness of percutaneous transhepatic biliary drainage in patients with surgical jaundice--a prospective randomised study. J Assoc Physicians India. 1999 Mar;47(3):271-4.</citation>
    <PMID>10999118</PMID>
  </reference>
  <reference>
    <citation>Fang Y, Gurusamy KS, Wang Q, Davidson BR, Lin H, Xie X, Wang C. Pre-operative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD005444. doi: 10.1002/14651858.CD005444.pub3. Review.</citation>
    <PMID>22972086</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krle A-Jerić K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015 Dec;38(6):506-14.</citation>
    <PMID>27440100</PMID>
  </reference>
  <reference>
    <citation>Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute pancreatitis. J Gastrointestin Liver Dis. 2015 Jun;24(2):177-82. doi: 10.15403/jgld.2014.1121.242.easy.</citation>
    <PMID>26114177</PMID>
  </reference>
  <reference>
    <citation>Párniczky A, Mosztbacher D, Zsoldos F, Tóth A, Lásztity N, Hegyi P; Hungarian Pancreatic Study Group and the International Association of Pancreatology. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial. Digestion. 2016;93(2):105-10. doi: 10.1159/000441353. Epub 2015 Nov 26.</citation>
    <PMID>26613586</PMID>
  </reference>
  <reference>
    <citation>Zsoldos F, Párniczky A, Mosztbacher D, Tóth A, Lásztity N, Hegyi P; Hungarian Pancreatic Study Group and the International Association of Pancreatology. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial. Digestion. 2016;93(2):121-6. doi: 10.1159/000441352. Epub 2015 Dec 4.</citation>
    <PMID>26641250</PMID>
  </reference>
  <reference>
    <citation>Dubravcsik Z, Madácsy L, Gyökeres T, Vincze Á, Szepes Z, Hegyi P, Hritz I, Szepes A; Hungarian Pancreatic Study Group. Preventive pancreatic stents in the management of acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial. Pancreatology. 2015 Mar-Apr;15(2):115-23. doi: 10.1016/j.pan.2015.02.007. Epub 2015 Feb 25.</citation>
    <PMID>25754525</PMID>
  </reference>
  <reference>
    <citation>Márta K, Szabó AN, Pécsi D, Varjú P, Bajor J, Gódi S, Sarlós P, Mikó A, Szemes K, Papp M, Tornai T, Vincze Á, Márton Z, Vincze PA, Lankó E, Szentesi A, Molnár T, Hágendorn R, Faluhelyi N, Battyáni I, Kelemen D, Papp R, Miseta A, Verzár Z, Lerch MM, Neoptolemos JP, Sahin-Tóth M, Petersen OH, Hegyi P; Hungarian Pancreatic Study Group. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. BMJ Open. 2017 Sep 14;7(9):e015874. doi: 10.1136/bmjopen-2017-015874.</citation>
    <PMID>28912191</PMID>
  </reference>
  <reference>
    <citation>Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Sahin-Tóth M, Szentkereszti Z, Szmola R, Takács T, Tiszlavicz L, Szücs Á, Czakó L; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group. [Autoimmune pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Orv Hetil. 2015 Feb 22;156(8):292-307. doi: 10.1556/OH.2015.30061. Review. Hungarian.</citation>
    <PMID>25662147</PMID>
  </reference>
  <reference>
    <citation>Hritz I, Czakó L, Dubravcsik Z, Farkas G, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Sahin-Tóth M, Szentkereszti Z, Szmola R, Szücs Á, Takács T, Tiszlavicz L, Hegyi P; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group. [Acute pancreatitis. Evidence-based practice guidelines, prepared by the Hungarian Pancreatic Study Group]. Orv Hetil. 2015 Feb 15;156(7):244-61. doi: 10.1556/OH.2015.30059. Review. Hungarian.</citation>
    <PMID>25661970</PMID>
  </reference>
  <reference>
    <citation>Szmola R, Farkas G, Hegyi P, Czakó L, Dubravcsik Z, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Párniczky A, Rubovszky G, Sahin-Tóth M, Szentkereszti Z, Szücs Á, Takács T, Tiszlavicz L, Pap Á; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group. [Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Orv Hetil. 2015 Feb 22;156(8):326-39. doi: 10.1556/OH.2015.30063. Review. Hungarian.</citation>
    <PMID>25662149</PMID>
  </reference>
  <reference>
    <citation>Takács T, Czakó L, Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Patai Á, Sahin-Tóth M, Szentkereszti Z, Szmola R, Tiszlavicz L, Szücs Á; Magyar Hasnyálmirigy Munkacsoport. [Chronic pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Orv Hetil. 2015 Feb 15;156(7):262-88. doi: 10.1556/OH.2015.30060. Review. Hungarian.</citation>
    <PMID>25661971</PMID>
  </reference>
  <reference>
    <citation>van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010 Jan 14;362(2):129-37. doi: 10.1056/NEJMoa0903230.</citation>
    <PMID>20071702</PMID>
  </reference>
  <reference>
    <citation>Sewnath ME, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma DJ. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 2002 Jul;236(1):17-27. Review.</citation>
    <PMID>12131081</PMID>
  </reference>
  <reference>
    <citation>Sun C, Yan G, Li Z, Tzeng CM. A meta-analysis of the effect of preoperative biliary stenting on patients with obstructive jaundice. Medicine (Baltimore). 2014 Nov;93(26):e189. doi: 10.1097/MD.0000000000000189.</citation>
    <PMID>25474436</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Szűcs</investigator_full_name>
    <investigator_title>Principal Investigator, Associate Professor of the First Surgical Department of the University of Semmelweis</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>biliary drainage</keyword>
  <keyword>pancreato-duodenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

